Nm23 gene expression and its correlation with lymph node metastasis in human lung cancer

1995 ◽  
Vol 7 (4) ◽  
pp. 235-238
Author(s):  
Lei Wendong ◽  
Zhang Rugang ◽  
Yan Shuizhong ◽  
Wang Xiuqin ◽  
Mu Juwei ◽  
...  
2015 ◽  
Vol 12 (4) ◽  
pp. 5217-5222 ◽  
Author(s):  
ZHIBIN JIANG ◽  
JIALIANG ZHU ◽  
YUCHAO MA ◽  
CAO HONG ◽  
SHENG XIAO ◽  
...  

Lung Cancer ◽  
2009 ◽  
Vol 64 (1) ◽  
pp. 86-91 ◽  
Author(s):  
Yasumitsu Moriya ◽  
Akira Iyoda ◽  
Yasuhiro Kasai ◽  
Takashi Sugimoto ◽  
Junya Hashida ◽  
...  

2016 ◽  
Vol 11 (1) ◽  
pp. 220-224
Author(s):  
Chongwei Wang ◽  
Chongbang Wang ◽  
Shufang Duan

AbstractObjectives: As the member of the Fox family of transcription factors, Forkhead box M1 (FoxM1) is known to be critical in pathogenesis and development of many solid tumors. However, the clinical value and expression pattern in non-small cell lung cancer (NSCLC) is still poorly understood. Methods: In this study, real-time PCR was mainly applied to examine the gene expression levels of FoxM1 in 120 pairs of clinical NSCLC tissues, which were classified into different groups according to smoking status, lymph node metastasis, and tumor grade. By utilizing the online Kaplan-Meier plotter, overall survival analysis was performed to study the correlation between FoxM1 expression and prognosis of lung cancer (LC) patients. Afterwards, the correlation of FoxM1 gene expression and the clinical pathological parameters was examined by κ2 test in these 120 NSCLC patients. Results: FoxM1 was found to be aberrantly upregulated in NSCLC patients, and its overexpression was correlated to groups designated as smokers, cases of positive lymph node metastasis and cases of advanced tumor grades. Online survival analysis showed that high expression of FoxM1 predicted shorter overall survival of NSCLC patients. Additionally, FoxM1 upregulation was statistically correlated with positive smoking history, lymph node metastasis and higher tumor grades. Conclusion: FoxM1 is overexpressed in cancerous tissues and is associated with the poor prognosis of NSCLC patients. Our results provide insights into the utility of FoxM1 as an important biomarker and prognostic factor for NSCLC.


1999 ◽  
Vol 11 (3) ◽  
pp. 188-191
Author(s):  
Liu Lun-xu ◽  
Zhou Qing-hua ◽  
Shi Ying-kang ◽  
Qin Yang ◽  
Sun Zhi-lin ◽  
...  

2012 ◽  
Vol 4 (6) ◽  
pp. 1325-1328 ◽  
Author(s):  
HIDEFUMI SASAKI ◽  
AYUMI SUZUKI ◽  
MASAYUKI SHITARA ◽  
YU HIKOSAKA ◽  
KATSUHIRO OKUDA ◽  
...  

Oral Oncology ◽  
2011 ◽  
Vol 47 ◽  
pp. S46
Author(s):  
F.K.J. Leusink ◽  
P.J. Slootweg ◽  
M.W.M. van den Brekel ◽  
R.J. Baatenburg de Jong ◽  
F.C.P. Holstege ◽  
...  

2021 ◽  
Vol 11 (2) ◽  
pp. 126
Author(s):  
Noshad Peyravian ◽  
Stefania Nobili ◽  
Zahra Pezeshkian ◽  
Meysam Olfatifar ◽  
Afshin Moradi ◽  
...  

This study aimed at building a prognostic signature based on a candidate gene panel whose expression may be associated with lymph node metastasis (LNM), thus potentially able to predict colorectal cancer (CRC) progression and patient survival. The mRNA expression levels of 20 candidate genes were evaluated by RT-qPCR in cancer and normal mucosa formalin-fixed paraffin-embedded (FFPE) tissues of CRC patients. Receiver operating characteristic curves were used to evaluate the prognosis performance of our model by calculating the area under the curve (AUC) values corresponding to stage and metastasis. A total of 100 FFPE primary tumor tissues from stage I–IV CRC patients were collected and analyzed. Among the 20 candidate genes we studied, only the expression levels of VANGL1 significantly varied between patients with and without LNMs (p = 0.02). Additionally, the AUC value of the 20-gene panel was found to have the highest predictive performance (i.e., AUC = 79.84%) for LNMs compared with that of two subpanels including 5 and 10 genes. According to our results, VANGL1 gene expression levels are able to estimate LNMs in different stages of CRC. After a proper validation in a wider case series, the evaluation of VANGL1 gene expression and that of the 20-gene panel signature could help in the future in the prediction of CRC progression.


Sign in / Sign up

Export Citation Format

Share Document